Jeff is a venture partner with over 25 years of experience in the biopharmaceutical industry bringing important new medicines to patients with cancer and rare diseases. He currently serves as board chairman of Blueprint Medicines, board director of Kymera Therapeutics and Magenta Therapeutics, and on the board of advisors for Life Sciences Cares. From 2014 to 2022, he served as CEO of Blueprint Medicines, which he led through an IPO and two FDA-approvals. Jeff previously served as President of Algeta until its acquisition by Bayer, and before that he held senior commercial and corporate development positions at Genzyme before its acquisition by Sanofi. Earlier in his career, Jeff was a life sciences corporate attorney at Mintz Levin. He holds a B.S. from Indiana University and an MBA and J.D. from Georgetown University.